Zacks upgraded shares of Rockwell Medical (NASDAQ:RMTI) from an underperform rating to a neutral rating in a research note issued to investors on Tuesday, Stock Ratings Network.com reports. The firm currently has $10.50 price target on the stock.
Zacks has also modified their ratings on a number of other healthcare stocks in the few days. The firm reiterated its neutral rating on shares of St. Jude Medical Inc.. They have a $57.00 price target on that stock. Also, Zacks reiterated its neutral rating on shares of Varian Medical Systems Inc.. They have a $78.00 price target on that stock.
Rockwell Medical (NASDAQ:RMTI) traded down 6.15% on Tuesday, hitting $9.15. The stock had a trading volume of 1,796,724 shares. Rockwell Medical has a 1-year low of $3.16 and a 1-year high of $11.80. The stock’s 50-day moving average is $6.34 and its 200-day moving average is $4.62. The company’s market cap is $365.2 million.
Several other analysts have also recently commented on the stock. Analysts at Craig Hallum initiated coverage on shares of Rockwell Medical (NASDAQ:RMTI) in a research note to investors on Friday, September 13th. They set a buy rating and a $16.00 price target on the stock. Separately, analysts at Summer Street raised their price target on shares of Rockwell Medical (NASDAQ:RMTI) from $20.00 to $25.00 in a research note to investors on Thursday, September 5th. They now have a buy rating on the stock. Finally, analysts at Summer Street reiterated a buy rating on shares of Rockwell Medical (NASDAQ:RMTI) in a research note to investors on Friday, August 2nd. They now have a $20.00 price target on the stock.
One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of $14.92.
Rockwell Medical, Inc, formerly Rockwell Medical Technologies, Inc, manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.